Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer

2006 ◽  
Vol 5 (8) ◽  
pp. 2096-2105 ◽  
Author(s):  
Qing-an Yuan ◽  
Heidi H. Simmons ◽  
Matthew K. Robinson ◽  
Maria Russeva ◽  
Wayne A. Marasco ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapy ◽  
Type Ii ◽  
Promising Candidate ◽  
Müllerian Inhibiting Substance ◽  
Mullerian Inhibiting Substance

scholarly journals Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer

2018 ◽  
Vol 59 (8) ◽  
pp. 1234-1242 ◽  
Author(s):  
Emmanuel Deshayes ◽  
Riad Ladjohounlou ◽  
Pierre Le Fur ◽  
Alexandre Pichard ◽  
Catherine Lozza ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Receptor Type ◽  
Type Ii ◽  
Müllerian Inhibiting Substance ◽  
Radiolabeled Antibodies ◽  
Mullerian Inhibiting Substance

scholarly journals The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer

mAbs ◽  
2014 ◽  
Vol 6 (5) ◽  
pp. 1314-1326 ◽  
Author(s):  
Nathalie Kersual ◽  
Véronique Garambois ◽  
Thierry Chardès ◽  
Jean-Pierre Pouget ◽  
Imed Salhi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Type Ii ◽  
Müllerian Inhibiting Substance ◽  
Immunotherapy Target ◽  
Mullerian Inhibiting Substance
Sign in / Sign up

Export Citation Format

Share Document